Wolverton Securities advisor believes in biotechnology

Santo Sandhu, an investment advisor with Wolverton Securities, said he believes the best opportunities right now lie in biotechnology.

That has led him to BioMark Diagnostics Inc., a Richmond B.C. company that is developing a cancer diagnostic system, using a known drug, which has already been approved by the U.S. Federal Drug Administration and Health Canada.

With phase 3 clinical trials under way in Bangladesh and Manitoba, Canada, the company has seen its stock price jump to $1.02 from 44 cents in early November.
Read more at http://www.stockhouse.com

Share this post:

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
FSE: 20B

Related articles ...

© 2024 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.